ClinicalTrials.gg
CompletedNCT02947269Updated Sep 29, 2021

Prucalopride in Postoperative Ileus

A Phase 3 interventional study of Prucalopride and Placebo Oral Capsule in Postoperative Ileus, Colorectal Surgery and Postoperative Complications, sponsored by University of Auckland, New Zealand. Completed at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by University of Auckland, New Zealand · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative ileus (POI) refers to the period of gut dysmotility that occurs after abdominal surgery. Patients with POI are unable to eat, suffer ongoing nausea and vomiting, are unable to open their bowels and have a prolonged hospital stay. Research at ADHB shows that 25% of patients will have a prolonged POI after elective bowel resection, which makes it the most common major complication after colorectal surgery. Clinicians currently lack a definitive medication to prevent or treat POI, which means POI causes patients ongoing morbidity and places a significant drain on healthcare resources. Serotonin plays an important role in gut motility. Evidence suggests that serotonin agonists, such as prucalopride, increase gut transit and may have anti-inflammatory properties. The hypothesis of this study is that Prucalopride given pre-operatively and continued post-operatively in patients having an elective bowel resection will improve gut function recovery after surgery and reduce POI.

The investigators' proposed study is a double-blinded randomised controlled trial of prucalopride compared to an identical placebo tablet, in patients having an elective bowel resection at Auckland City Hospital. Patients will receive a single tablet of Prucalopride or placebo 2-3 hours preoperatively and then daily after operation for a maximum of 6 days. The primary endpoint will be return to bowel function defined by the time to tolerate a solid diet and pass stool. In addition, the investigators plan to assess postoperative gastric emptying rates using the safe and non-invasive carbon breath test method. This will allow the investigators to determine the effects of prucalopride on the stomach, and support its role as a gastric prokinetic.

02

Conditions studied

  • Postoperative Ileus
  • Colorectal Surgery
  • Postoperative Complications
03

In context

Postoperative Complications

1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

This study's enrollment of 150 is above the median of 114 across 770 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

University of Auckland, New Zealand is the lead sponsor of 57 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients from Auckland District Health Board catchment
  • Age 18 or older
  • Elective and subacute surgery
  • Right hemicolectomy, left hemicolectomy, sigmoid colectomy, anterior resection, Hartmann's procedure, subtotal colectomy
  • Operation with or without the formation of a colostomy
  • Indication for operation: colon cancer, diverticular disease, gynaecological
  • Able to understand risks and benefits of the study
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • ASA 4 or greater
  • Allergy to any serotonin medication
  • Active inflammatory bowel disease
  • Planned formation of an ileostomy during surgery
  • Moderate to severe renal impairment (\<50mL/min/1.73m2)
  • Severe hepatic impairment ( C)
  • Pregnancy
  • Pre-existing gut dysmotility disorder including endocrine, metabolic or neurological cause
  • Pre-operative malnutrition requiring parenteral nutrition
  • Inability to give consent or participate in post-operative assessments due to dementia, cognitive impairment, language difficulties, delirium
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Intervention group

    Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.

    Drug: Prucalopride

  • Placebo comparator
    Placebo group

    Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.

    Drug: Placebo Oral Capsule

Interventions

  • Prucalopride 2mg capsule

    Also known as: Resolor, Resotrans

  • DrugPlacebo Oral Capsule

    Placebo capsule

06

What researchers measure

Primary outcomes

  1. Time until recovery of gastrointestinal function

    Recovery of GI function is defined by the later time point (in days) of time to passage of stool AND time to tolerance of a solid or semi-solid diet. Patients will be reviewed twice per day using a structured questionnaire.

    Time frame: From date of surgery until discharge from hospital (14 days on average)

Secondary outcomes

  1. Time until passage of stool (in days)

    Time frame: From date of surgery until discharge from hospital (14 days on average)

  2. Time until passage of flatus (in days)

    Time frame: From date of surgery until discharge from hospital (14 days on average)

  3. Time until tolerance of solid oral diet (in days)

    Time frame: From date of surgery until discharge from hospital (14 days on average)

  4. Presence of prolonged postoperative ileus

    Prolonged postoperative ileus is defined as presence of 2 or more of the following criteria on or after day 4 postoperatively: nausea or vomiting, inability to tolerate a solid or semi-solid oral diet, abdominal distension, absence of flatus and stool, radiological evidence of ileus.

    Time frame: From date of surgery until discharge from hospital (14 days on average)

  5. Levels of serum inflammatory markers (in pg/mL)

    Markers to be tested: CRP, IL1beta, IL6, IL8, IL12, TNFalpha

    Time frame: Inflammatory markers will be collected preoperatively, day 1 and 3 postoperatively. Blood samples will be stored after collection for later testing (up to 1 year).

  6. Length of postoperative stay (in days)

    Time frame: From date of surgery until discharge from hospital (14 days on average)

Other outcomes

  1. Rate of gastric emptying using the 13-carbon octanoate breath test

    A subgroup of 40 patients will be investigated for this study

    Time frame: This test will be undertaken on day 2 postoperatively, and will take approximately 4 hours

07

Study locations

1 site
  • University of Auckland
    Auckland, 1023, New Zealand
08

References and documents

Publications

  • Milne T, Liu C, O'Grady G, Woodfield J, Bissett I. Effect of prucalopride to improve time to gut function recovery following elective colorectal surgery: randomized clinical trial. Br J Surg. 2022 Jul 15;109(8):704-710. doi: 10.1093/bjs/znac121. PubMed 35639621 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Aug 2020, 34 months.

Of 20 phase 3 interventional studies under Postoperative Complications, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2016
First posted
Oct 27, 2016
StartActual
Oct 25, 2017
Primary completionActual
Aug 30, 2020
CompletionActual
Aug 30, 2020
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02947269
Lead sponsor
University of Auckland, New Zealand
Responsible party
A/Prof Ian Bissett (Professor Ian Bissett, University of Auckland, New Zealand) — Principal investigator
First posted
Oct 27, 2016
Start date
Oct 25, 2017
Primary completion
Aug 30, 2020
Completion
Aug 30, 2020
Last update
Sep 29, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prucalopride

Start the discussion